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Abstract The dephosphorylation of the myosin light chain
kinase and protein kinase C sites on the 20 kDa myosin light
chain by myosin phosphatase was investigated. The myosin
phosphatase holoenzyme and catalytic subunit, dephosphorylated
Ser-19, Thr-18 and Thr-9, but not Ser-1/Ser-2. The role of non-
catalytic subunits in myosin phosphatase was to activate the
phosphatase activity. For Ser-19 and Thr-18, this was due to a
decrease in Km and an increase in kcat and for Thr-9 to a
decrease in Km. Thus, the distinction between the various sites is
a property of the catalytic subunit.
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1. Introduction
It is established that the contractile activity in smooth
muscle and non-muscle cells is regulated by a mechanism
that involves phosphorylation and dephosphorylation of the
20 kDa light chain of myosin (MLC20) 1 [1]. Under most
experimental conditions, MLC20 can be phosphorylated to
1 mol P/mol MLC20 by the myosin light chain kinase
(MLCK) and the site of phosphorylation has been identi¢ed
as Ser-19 [2]. At high concentrations of MLCK, a second site
is phosphorylated and this site is Thr-18 [3]. MLC20 can also
be phosphorylated by Ca2-activated, phospholipid-depend-
ent protein kinase (PKC) on distinct serine and threonine
residues [4^6]. Three potential sites of in vitro phosphoryla-
tion have been identi¢ed as Ser-1, Ser-2 and Thr-9 [6]. Other
kinases such as calmodulin-dependent protein kinase II [7],
Rho-associated kinase [8] and the p21-activated protein kinase
[9] also phosphorylate MLC20 at Ser-19. In general, phos-
phorylation at Ser-19 and Thr-18 activates the actin-activated
ATPase activity of myosin, while the PKC sites have an in-
hibitory e¡ect [3^6].
On the other hand, the phosphatases that dephosphorylate
myosin are not as well understood. A number of protein
phosphatases have been reported that can dephosphorylate
MLC20 at Ser-19 at least in vitro [10]. Some are also involved
in dephosphorylation of other sites, i.e. Thr-18 and Ser-19 by
MLCK [4,11], Ser-1, Ser-2 and Thr-9 by PKC [6,11]. Re-
cently, a myosin phosphatase (MP) e¡ective with intact phos-
phorylated myosin as a substrate was isolated from smooth
muscle (reviewed in [12]). This MP was composed of three
subunits : 110, 38 and 20 kDa. The 38 kDa subunit is the N
isoform of the catalytic subunit of type 1 protein phosphatase
(PP1cN) (also referred to as PP1cL) and the 110 kDa subunit is
a putative regulatory or target molecule for myosin and
PP1cN. The function of the 20 kDa regulatory subunit
(M20) is not known. MP was found to account for nearly
all of the MP activity in myo¢brils [13] and thus it is generally
accepted that the trimeric MP is the major phosphatase for
myosin in smooth muscle [12]. Recently, MP has attracted the
attention because its regulatory mechanisms may be linked to
the Ca2 sensitization of smooth muscle contraction [14].
All previous studies on MP have focused on the dephos-
phorylation of Ser-19 and dephosphorylation of other sites
has not been considered. In this article, it is shown that MP
dephosphorylates both of the MLCK sites, Ser-19 and Thr-18,
but only dephosphorylates one of the PKC sites, i.e. Thr-9.
The ability of MP to discern between sites is a property of the
catalytic subunit PP1cN and does not require the non-catalytic
subunits. Kinetic analyses show that the e¡ect of the non-
catalytic subunits is to increase the rate of dephosphorylation
for the di¡erent sites.
2. Materials and methods
2.1. Chemicals
[Q-32P]ATP (3000 Ci/mmol) was obtained from Du Pont-NEN (Bos-
ton, MA, USA), phorbol 12-myristate 13-acetate, L-K-phosphatidyl-L-
serine, TPCK-treated trypsin, L-phosphoserine, L-phosphothreonine
and L-phosphotyrosine from Sigma Chemical (St. Louis, MO,
USA), microcystin-LR from Wako Pure Chemical (Osaka, Japan).
All other chemicals were of reagent grade.
2.2. Protein preparations
MP was puri¢ed from chicken gizzard as described previously [15].
Smooth muscle myosin, MLC20, PP1cN and MLCK from chicken
gizzard and calmodulin from bovine brain were puri¢ed as listed
previously [16]. PKC was puri¢ed from human platelets as described
previously [17].
2.3. Preparation of 32P-labelled substrate
Phosphorylation of myosin at Ser-19 was carried out as follows:
myosin (5 mg/ml) was incubated at 30‡C for 12 min with 5 Wg/ml
calmodulin and 10 Wg/ml MLCK in solvent A (20 mM Tris-HCl, pH
7.5, 1 mM MgCl2, 300 mM KCl, 0.1 mM CaCl2, 1 WM microcystin-
LR and 0.5 mM [Q-32P]ATP. Phosphorylation of myosin at Ser-19
plus Thr-18 was carried out at as follows: myosin (5 mg/ml) was
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incubated at 30‡C for 20 min with 20 Wg/ml calmodulin and 100 Wg/ml
MLCK in solvent A. Phosphorylation of myosin at Thr-9, Ser-1 and/
or Ser-2 by PKC was carried out as follows: myosin (5 mg/ml) was
incubated at 30‡C for 2 h with 10 Wg/ml PKC in 20 mM Tris-HCl, pH
7.5, 1 mM MgCl2, 300 mM KCl, 1 mM EGTA, 100 ng/ml phorbol
12-myristate 13-acetate, 100 Wg/ml L-K-phosphatidyl-L-serine, 1 WM
microcystin-LR and 0.5 mM [Q-32P]ATP [6]. The levels of phospho-
rylation obtained were 1.9, 3.9 and 3.4 mol P/mol myosin, respec-
tively. The phosphorylated samples were dialyzed against 30 mM
Tris-HCl, pH 7.5, 300 mM KCl and 0.2 mM dithiothreitol. 32P-la-
belled MLC20 at Ser-19 plus Thr-18 by MLCK and at Thr-9, Ser-1
and/or Ser-2 by PKC were prepared as described previously [18].
2.4. Phosphatase assays
Phosphatase assays were carried out at 30‡C using 32P-labelled
myosin (¢nal concentration 2 WM) or 32P-labelled MLC20 as the
substrate (¢nal concentration 5 WM). The assay conditions were 30
mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM MgCl2, 1 mM ATP, 0.2
mg/ml bovine serum albumin and enzyme as indicated in the ¢gure
legends. The reactions were started by the addition of substrate and
terminated by the addition of trichloroacetic acid to 5%. After sed-
imentation at 5000Ug for 5 min, the radioactivity of the supernatant
was determined by Cerenkov counting.
2.5. Determination of the sites of dephosphorylation on the myosin light
chain
Aliquots of phosphorylated myosin were resolved by 10% SDS-
PAGE and stained with Coomassie blue. The bands corresponding
to MLC20 were excized and processed for the digestion (in the gel) by
TPCK-treated trypsin [19]. A two dimensional phosphoamino acid
analysis was then performed [20].
2.6. Other procedures
SDS-PAGE was carried out with the discontinuous bu¡er system of
Laemmli [21]. Protein concentrations were determined with either the
BCA (Pierce) or Bradford (Bio-Rad) procedures, using bovine serum
albumin as a standard.
3. Results
To determine if MP of smooth muscle could dephospho-
rylate both of the MLCK sites, the phosphatase rate was as-
sayed using double-labelled myosin by MLCK (3.9 mol P/mol
myosin). The time courses of dephosphorylation by the MP
holoenzyme and PP1cN are shown in Fig. 1A and B, respec-
tively. Both the holoenzyme and PP1cN dephosphorylated
double-labelled myosin (Thr-18/Ser-19) almost completely,
suggesting that MP and PP1cN are e¡ective with both of the
MLCK phosphorylation sites. The insets of Fig. 1 show semi-
logarithmic plots of the time course data and single ¢rst order
rate processes are indicated. These results suggest that both
the MP holoenzyme and PP1cN have no apparent preference
for Thr-18 or Ser-19. The MP holoenzyme and PP1cN also
completely dephosphorylated double-labelled MLC20 (data
not shown).
Dephosphorylation of the PKC sites was studied next using
myosin phosphorylated by PKC (3.4 mol P/mol myosin). As
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Fig. 1. Dephosphorylation of doubly phosphorylated myosin. Myosin was phosphorylated to 3.9 mol P/mol myosin by MLCK and the double
32P-labelled myosin was assayed with 1 Wg/ml of MP holoenzyme (A) and 10 Wg/ml of PP1cN (B) as described in Section 2. Insets show semilo-
garithmic plots of time course data, where Pmax is the experimental maximum level of phosphorylation and Pt is the phosphorylation at time t.
Fig. 2. Dephosphorylation of multiple phosphorylated myosin. Myosin was phosphorylated to 3.4 mol P/mol myosin by PKC and the multiple
32P-labelled myosin was assayed with 1 Wg/ml of MP (A) and 10 Wg/ml of PP1cN (B) as described in Section 2.
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shown in Fig. 2, the dephosphorylation achieved by MP hol-
oenzyme and PP1cN was only partial. After 10 min incuba-
tion, only about 30^40% of the total phosphate was released
and the remaining sites were resistant to further dephospho-
rylation. With MLC20 phosphorylated by PKC as substrate,
similar results were obtained (data not shown). These results
suggest that between the three potential PKC sites, there is
some preference as substrates for the holoenzyme and PP1cN.
When myosin is phosphorylated by PKC to 3.4 mol P/mol
myosin, both phosphoserine and phosphothreonine were de-
tected (Fig. 3A). After dephosphorylation by MP (Fig. 3B),
phosphothreonine disappeared and about 90% of the radio-
activity was present as phosphoserine. In the control sample
(no phosphatase treatment), both phosphoserine and phos-
phothreonine were detected. These results indicated that of
the three PKC sites only Thr-9 can be e¡ectively dephos-
phorylated by the MP holoenzyme. Similar results were ob-
tained with PP1cN (data not shown).
Phosphatase assays were carried out to determine kinetic
parameters of MP and PP1cN using mono-phosphorylated
myosin (Ser-19), di-phosphorylated myosin (Thr-18/Ser-19)
and the multi-phosphorylated myosin (Thr-9, Ser-1 and/or
Ser-2). The respective values are compared in Table 1. The
following points should be made: (1) with mono-phosphoryl-
ated and di-phosphorylated myosin as substrates, the e¡ects
of the holoenzyme were about a 10-fold decrease in Km and a
9-fold increase in kcat, compared to PP1cN. (2) With PKC-
phosphorylated myosin as substrate, the holoenzyme showed
a 5-fold decrease in Km but had no e¡ect on kcat.
4. Discussion
The above results document that the dephosphorylation of
both Ser-19 and Thr-18 can be catalyzed by the MP holoen-
zyme. A single rate of dephosphorylation was indicated thus
implying a lack of preference between the two sites. Diphos-
phorylation of MLC20 at Thr-18 and Ser-19 has been ob-
served not only in vitro [3,4] but also in intact smooth muscles
following agonist stimulation [22,23]. In vitro experiments
show that diphosphorylation of Thr-18 and Ser-19 increases
the actin-activated ATPase activity of myosin [3,4] and stabil-
izes myosin ¢laments [24]. However, some e¡ects of diphos-
phorylation of MLC20 are controversial. In permeabilized
smooth muscle ¢ber preparations, the additional phospho-
rylation at Thr-18 did not a¡ect the tension and shortening
velocity [25], nor did it increase the velocity of myosin-coated
beads in the in vitro mobility assays [26]. On the other hand,
diphosphorylation of MLC20 has been reported to correlate
in situ with thrombin-induced platelet aggregation [27] and
with the rate and extent of degranulation in RBL-2H3 cells
[28]. It is interesting that treatment with 10^100 nM calyculin
A (a protein phosphatase inhibitor) in SM-3 cells [29] or gua-
nosine 5P-O-(3-thiotriphosphate), which is thought to inhibit
MP, in permeabilized pig aortic smooth muscle cells [30],
strongly induced diphosphorylation of MLC20. In addition,
diphosphorylation of MLC20 was observed in various patho-
logical models, including intimal hyperplasia in rabbit carotid
artery [31] and coronary artery spasm in a swine model [32].
Whether the generation of di-phosphorylated MLC20 is
caused in part by the inhibition of MP in spasm smooth
muscle is an interesting point but is beyond the scope of the
present study. Thus, these data suggest that if diphosphoryla-
tion (by MLCK) occurs under physiological conditions, both
sites would be subject to dephosphorylation by MP.
Phosphorylation of MLC20 by PKC has also been demon-
strated in vitro for smooth muscle [4^6] and non-muscle my-
osin [33^38]. Although the e¡ects of PKC phosphorylation of
myosin in the smooth muscle system remain obscure, possible
e¡ects of phosphorylation at the PKC sites in human platelets
[33,35] and the mast cell line RBL-2H3 [36] have been pro-
posed. Yamakita et al. [37] demonstrated the importance of
phosphorylation of myosin on Ser-1 and Ser-2 catalyzed by
cdc2 kinase in mitotically arrested cells. Our results show that
MP e¡ectively dephosphorylated Thr-9, whereas the other two
sites (Ser-1 and/or Ser-2) were resistant to the phosphatase.
Recently, evidence has accumulated to indicate that phos-
phorylation of Ser-1 and/or Ser-2 was detectable in intact
smooth muscle and non-muscle cells, but phosphorylation of
Thr-9 was not detectable in vivo ([28,29,35,36,39]). On the
other hand, Turbedsky et al. [40] found that phosphorylation
of Ser-1/Ser-2 of the Xenopus myosin regulatory light chain
did not inhibit the subsequent phosphorylation of Ser-19 by
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Fig. 3. Determination of the dephosphorylation site. Aliquots of
[32P]myosin phosphorylated by PKC were incubated without (A) or
with 1 Wg/ml of MP (B) for 60 min and then the samples were sub-
jected to the phosphoamino acid analysis as described in Section 2.
The radioactive spots were scraped from the thin layer plates and
the radioactivities corresponding to phosphoserine and phospho-
threonine were determined by Cerenkov counting. P-Ser, phospho-
serine; P-Thr, phosphothreonine; P-Tyr, phosphotyrosine.
Table 1
Kinetics of MP and PP1cN for distinct phosphorylated myosina
Substrates MP PP1cN
Km (WM) kcat (WM) Km (per min)b kcat (per min)b
Myosin (Ser-19) 4.3 þ 0.9 791 þ 27 39.3 þ 3.3 115 þ 14
Myosin (Thr-18/Ser-19 7.4 þ 2.1 949 þ 52 44.7 þ 4.1 106 þ 17
Myosin (Ser-1/Ser-2/Thr-9 12.2 þ 1.5 82.6 þ 17.3 59.2 þ 3.8 80.6 þ 11.5
aValues are means þ S.D. (n = 3). bThe molecular weights used were 168 kDa for MP and 37 kDa for PP1cN.
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MLCK and suggested that the inhibition of MLCK was due
to phosphorylation of Thr-9 and secondary sites Thr-7 and
Thr-10. Thus, it is suggested that if phosphorylation of Thr-9
is involved in a given process, the relevant phosphatase is a
type 1 enzyme, as in MP. If Ser-1/Ser-2 are phosphorylated
then it is likely that a di¡erent phosphatase is required.
Several protein phosphatases isolated from smooth muscle
tissues have been reported to dephosphorylate multiple sites
on MLC20. Ikebe et al. showed that a spontaneously active
phosphatase from bovine aorta could dephosphorylate Ser-19,
Thr-18 and Thr-9 but not Ser-1 and Ser-2 [4,6]. Erdoºdi et al.
also reported that the catalytic subunit of a heparin-agarose
bound phosphatase e¡ectively dephosphorylated Thr-18, Ser-
19 and Thr-9, whereas it was less e¡ective in dephosphoryla-
tion of Ser-1 and Ser-2 in actomyosin [11]. The site preference
for these phosphatases is similar to MP, suggesting that they
may be related, possibly via the PP1 catalytic subunit.
The catalytic subunit, PP1cN, showed the same site selection
as the holoenzyme. In this respect it di¡ers from PP2A, since
Ser-19 of MLC20 in intact myosin was de-phosphorylated by
PP2Ac but not by PP2A holoenzyme [41]. The role of the
non-catalytic subunit in MP, therefore, is to activate PP1cN,
as suggested in earlier studies [12,16]. Activation was observed
for each of the three sites and for Ser-19 and Thr-18 was
achieved by a decrease in Km and an increase in kcat. For
Thr-9, the activation was primarily due to a decrease in Km.
Thus, it is suggested that an important factor in the activation
of the phosphatase activity as seen for the holoenzyme, re-
£ects an increased a⁄nity of binding to the phosphorylated
substrate. Probably, this is due to targeting via the large non-
catalytic subunit.
In summary, we showed that MP is e¡ective with Ser-19,
Thr-18 and Thr-9, but ine¡ective with Ser-1 and/or Ser-2 of
MLC20 in intact myosin. The ability to discern among these
sites is a property of the catalytic subunit, PP1cN, and does
not require the non-catalytic subunits.
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